Key Takeaways
- H1 soft, H2 rebound promised: Consolidated revenue grew ~5% YoY in Q2 (11% gross-adjusted) but management targets 18–20% full-year growth, implying a sharp second-half ramp driven by lumpy built-to-spec defense deliveries.
- Fundraise signals growth ambition, not distress: The planned ₹250 crores equity raise is earmarked for working capital and capex to support growth over the next two years, with management stating current debt has peaked.
- Standalone is the engine, subsidiary the fixer-upper: Standalone business is growing at 25%-plus and that pace is the target going forward; the subsidiary drags consolidated growth while management focuses on making it profitable.
- Margin recovery hinges entirely on H2 BTS deliveries: Full-year EBITDA margin is guided to 10–11%, requiring a significant second-half lift after a poor first half in the lumpy built-to-spec segment.
- What to watch next quarter: Whether the promised H2 BTS order conversion actually materializes, the pace of subsidiary profitability improvement, and any closure on the long-pending Indra system commercial bid.
Growth & Revenue Trajectory
- Q2 softness explained: Consolidated revenue grew only ~5% YoY because a specific contract was accounted for on a net basis; on a gross-adjusted basis, growth was 11%. The second quarter is also seasonally the slowest for the subsidiary due to fewer working days.
- H2 ramp mechanics: Second-half performance is expected to improve significantly, driven by increased built-to-spec deliveries to defense and space customers, plus enhanced performance in both EMS and the subsidiary. The BTS business is seasonal and lumpy: a very poor first half gets compensated in the second.
- Standalone vs consolidated divergence: Standalone growth has been 25%-plus and that is the target going forward. The 20% consolidated growth target for the next couple of years includes the subsidiary, where top-line growth will be sacrificed while management fixes profitability.
- Order pipeline supports the growth call: Order booking for domestic defense and space is progressing well, with a substantial space program order announced last quarter. More significant opportunities are expected in line systems and military radars. The EMS pipeline is strong from existing defense customers, with order intake rising from export customers due to the global geopolitical situation.
- New customer additions: New customers were added in the industrial equipment segment last quarter, illustrating China-plus-one and Make in India dynamics. These are expected to grow substantially in the next one to two years. One specific Make in India customer opportunity is hopeful of closing this quarter or this year.
Management: "if you look at a standalone basis, our growth rate has been much more than 20%. We've growing at 25%-plus. And so that's what we are targeting for going forward as well."
Fundraising & Balance Sheet
- Equity raise of up to ₹250 crores: The company is looking to raise equity to fund growth, predominantly for increased working capital and capital expenditure to augment capacities. The quantum is intended to cover needs for at least the next two years.
- Why equity, not debt: Management stated that since debt is already on the balance sheet, equity was the better choice considering debt-equity and leverage. Current debt levels are described as the peak and will not go up; the company expects to bring debt down.
- Capex outlook: Total capex for the next couple of years is expected to be in the range of about ₹100 crores.
- Dividend policy unchanged: The company wants to remain a consistent dividend-paying company, with a stated policy of distributing 20% to 25% of profits.
- No incremental revenue quantified: When asked what incremental revenue the fundraise could generate, management did not provide a figure, noting the number is still being evaluated and may be slightly lower than the stated cap.
Management: "predominantly, it will be for the increase in working capital, and also the capital expenditure that we need to incur to ensure that growth happens. Since we already have a debt on our balance sheet, we thought it would be better to look at the opportunity of raising it to equity and that is what we are looking at."
Margin Structure & Profitability Path
- Full-year margin target intact: Management is targeting 10% to 11% EBITDA margin for the full year, implying a significant second-half lift. Full-year EBITDA is targeted at approximately ₹130 crores.
- H2 margin driver is BTS seasonality: The increase in EBITDA margin in the second half is mainly because the BTS business, which was very poor in the first half, will compensate in the second. Management advised taking a full-year perspective.
- Medium-term margin ambition: Over the next 2–3 years, the company expects to reach 14% or 15% EBITDA margin. Achieving this depends on improving subsidiary EBITDA margins up to that level, which will take the two-year timeframe mentioned.
- Employee cost trajectory: Employee cost reduced YoY due to VRS schemes taken last quarter. Going forward, employee cost will not go up significantly: the quarterly run-rate is expected at ~₹88 to ₹90 crores for the next two quarters, with normal single-digit growth over the next two years from inflation and some headcount additions. The workforce is mostly fixed in nature, on roles rather than contract.
- Margins and single-source status: Margins are determined more by the engagement model than by being a single-source supplier. EMS operates on a cost-plus model with costs transparent to the customer; retention comes from consistent quality and on-time delivery, not pricing power.
- Finance cost outlook: Finance cost will remain in the same range, at a maximum of ₹40 crores. However, this includes bank commission on bank guarantees, which may increase if future contracts require more guarantees.
- Tax rate: Consolidated tax rate will be definitely less than 25%, though management declined to give a specific number for next year, calling it too early.
Subsidiary Turnaround
- Profitability timeline: The subsidiary is expected to have a positive contribution in Q3 and Q4 of this year, with actual profitability starting to kick in from FY26.
- Seasonality matches the parent: The subsidiary is also seasonal: Q2 is always the slowest quarter due to the fewest working days, while Q4 is the highest.
- Consolidated growth trade-off: The 20% consolidated growth target for the next couple of years embeds slower top-line growth at the subsidiary while management focuses on fixing issues and making it profitable. The shortfall is compensated by higher standalone growth.
Management: "The question of 25% of 20%, when we said 20% for the next couple of years, that includes the subsidiary, where our focus is more on fixing the issue and making it profitable so that the top line may not grow like 20%. So that has to be compensated by a higher growth in the standalone company."
Strategic Direction & Pipeline
- Moving up the value chain: The company has no plans to enter OSAT; the strategic direction is to move up the value chain by designing and developing full systems products.
- Defense and space pipeline: More significant opportunities are expected in line systems and military radars for the rest of the year. The order pipeline is described as healthy.
- EMS export momentum: Order intake from export customers has increased due to the global geopolitical situation, alongside new customer additions in industrial equipment reflecting China-plus-one and Make in India stories.
- Indra system status unchanged: The MOU status remains the same; the company is still waiting on budget allocations from the government. The RFP has been submitted, but the government's decision to proceed with commercial bid opening is delayed.
- New platforms like Vedanta: No short-term impact is expected from new domestic platforms. Longer term, management hopes for a better ecosystem in India to attract more global customers.
Management: "In fact, I would say our point there is more in terms of moving up the value chain rather than down the value chain. So designing, developing full systems products is one part that we would like to pursue going forward."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Consolidated revenue growth | 18% to 20% (accounting for the specific net-basis contract) | Full year FY25 |
| EBITDA margin | 10% to 11% | Full year FY25 |
| Full-year EBITDA | ~₹130 crores | Full year FY25 |
| Employee cost quarterly run-rate | ~₹88 to ₹90 crores per quarter | Next two quarters |
| Employee cost growth | Normal single-digit growth (inflation + some headcount) | Next two years |
| Standalone growth rate | 25%-plus | Going forward |
| Consolidated growth rate | 20% (including subsidiary) | Next couple of years |
| EBITDA margin target | 14% to 15% | Next 2–3 years |
| Subsidiary contribution | Positive contribution | Q3 and Q4 FY25 |
| Subsidiary full profitability | Actual profitability starts to kick in | FY26 |
| Capex | ~₹100 crores total | Next couple of years |
| Consolidated tax rate | Definitely less than 25% | Ongoing |
| Finance cost | Maximum ₹40 crores (subject to bank guarantee requirements) | Ongoing |
| Debt trajectory | Current level is the peak; will be brought down | Ongoing |
| Dividend payout | 20% to 25% of profits distributed | Per stated policy |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Consolidated revenue from operations | ₹260 cr, +4.7% YoY |
| Revenue growth (as reported) | ~5% YoY |
| Revenue growth (adjusted to gross value) | 11% YoY, 10% for H1 FY25 |
| Gross value of contract accounted on net basis | ₹15 cr in Q2, ₹39 cr for H1 FY25 |
| EBITDA | ₹20 cr, +18% YoY |
| Full-year consolidated revenue growth target | 18% to 20% (accounting for specific contract); ~14% to 15% if net accounting continues |
| Full-year EBITDA margin target | 10% to 11% |
| Full-year EBITDA target | ~₹130 cr (per an analyst's math, confirmed by management) |
| Employee cost quarterly run-rate (forward guidance) | ₹88 to ₹90 cr per quarter |
| Standalone growth rate (historical) | 25%-plus in past years |
| Debt on standalone balance sheet | ~₹130 cr |
| Debt in subsidiary | ~₹60 cr |
| Fundraise planned | Up to ₹250 cr, may be slightly lower, for next 2 years |
| Dividend policy | 20% to 25% of profits distributed |
| Revenue mix: BTS | ~25% of revenue |
| Revenue mix: Engineering services | ~30% of revenue |
| Revenue mix: EMS | ~45% of revenue |
| Single source supplier | 80% of cases |
| Capex guidance (next 2 years combined) | ~₹100 cr, ~₹50 cr per annum |
| Standalone tax rate | 25% |
| Consolidated tax rate | Less than 25% |
| Annualized finance cost | ₹35 to ₹40 cr (per an analyst's math), maximum ₹40 cr |
| Subsidiary profitability expectation | Positive contribution in Q3 and Q4 |